« Return to News | CROs/Service Providers

Quintiles acquires Outcome Sciences

Wednesday, October 19, 2011 12:52 PM

With late phase research becoming increasingly important to multiple healthcare stakeholders, Quintiles has acquired Outcome Sciences, a privately held outcomes research firm headquartered in Cambridge, Mass.

Observational research encompasses registries, post-approval research and quality improvement initiatives across multiple healthcare stakeholders (biopharmaceutical, medical device, government and providers). Since its founding in 1998, Outcome has designed, developed and managed more patient registries and post-approval studies than any other company. Outcome’s programs across more than 40 therapeutic areas include thousands of sites and millions of patients in more than 80 countries.

“This acquisition underscores Quintiles’ commitment to delivering efficient, insightful late phase solutions to help customers show the value of their products to patients, providers and payers,” said Quintiles president and chief operating officer John Ratliff. “The phase IIIB/IV market is forecast to reach more than $4 billion by 2015, up significantly from 2010. We estimate that observational research accounts for about 30% of that market, and Outcome is the notable leader in it. With this acquisition, no other biopharmaceutical services company can match Quintiles’ level of late phase science and strategy, global reach and service specialization."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.